Introduction
Cancer involves significant changes in the normal behaviour of cells, making them divide continuously, which interferes with normal physiology of the body (Cooper & Hausman Reference Cooper and Hausman2007; Jain et al., Reference Jain, Sengupta and Jain2019; Jain, Reference Jain2024). Carcinogens are agents capable of cancer induction that takes place mostly by genetic mutations. At the genetic level, a ‘gain-of-function’ mutation in proto-oncogenes like Her-2/Neu, Raf, Ras or a ‘loss-of-function’ mutation in tumour suppressor genes like p53, Rb1, and BRCA1 lead to cancer induction (Lodish et al Reference Lodish, Berk, Zipursky, Matsudira, Baltimore and Darnell2003; Jain & Kumar, Reference Jain and Kumar2020).
Helminths are worm-like parasites with flat, elongated or round bodies and they generally develop through egg, larval and adult stages (Roberts et al., Reference Roberts, Janovy and Nadler2012). Helminths belonging to three genera, namely Schistosoma, Clonorchis and Opisthorchis, have been classified as human carcinogens by International Agency for Research on Cancer (IARC) (Jain et al., Reference Jain, Rana, Choubey and Kumar2023). IARC classifies carcinogens into three different groups on the basis of evidence of their cancer-causing ability towards humans. Group 1 agents are carcinogenic to humans whereas those in group 2 are plausible carcinogens which lack a confirmatory evidence of their carcinogenicity towards humans. Group 2 is bifurcated into two sub-groups: 2A (probable carcinogens) and 2B (possible carcinogens). Importantly, the terms ‘probable’ and ‘possible’ have no quantitative significance and only depict different levels of evidence of carcinogenicity, with group 2A agents having a relatively higher level of evidence for human carcinogenicity. Agents in group 3 are non-classifiable due to lack of sufficient amount of data for their carcinogenic abilities in humans (Jain & Rana, Reference Jain and Rana2024; Jain, Reference Jain2024).
In 2020, liver cancer (LC) has been identified as third leading cause of cancer deaths worldwide and is the sixth most commonly diagnosed cancer. Approximately 830,000 deaths were reported in 2020, with mortality among men being higher than women. LC primarily includes hepatocellular carcinoma (HCC; 75%–85%) and intrahepatic cholangiocarcinoma (10%–15%) and other rare LC types like fibrolamellar carcinoma, hepatoblastoma and liver angiosarcoma (Sung et al., Reference Sung, Ferlay, Siegel, Laversanne, Soerjomataram, Jemal and Bray2021).
Recent studies have linked Schistosoma japonicum (Sj) infection with LC. LC linked with Sj (SJLC) has been a focus of research but the association is still understudied. The IARC has placed Sj in group 2B (i.e., possible carcinogen) (IARC, 1994). Hence, the aim of this review is multi-directional. First, it presents multiple studies, including epidemiological, pathological and clinical studies which link Sj with LC. It is followed by a detailed explanation of probable induction mechanism along with discussion of third-party risk factors (hepatitis viruses) and contrasts it with induction of LCs not associated with Sj. Finally, the work further looks into diagnosis and treatment modalities for SJLC and comments upon the current understanding of the probable causal role of Sj in liver carcinogenesis.
1. Schistosoma japonicum: Life cycle and Schistosomiasis
Schistosomes are ordinarily known as blood flukes and are largely parasitic to warm-blooded vertebrates and cause Schistosomiasis (Roberts et al., Reference Roberts, Janovy and Nadler2012). Schistosomiasis is a unique disease as almost the entire pathogenesis occurs due to eggs and not adult worms. The female deposits the eggs into smaller veins which then traverse the walls of venule, some tissues, and bladder or gut mucosa (depending upon the species of Schistosoma) and reaches a position from where they can be expelled from the human host (Colley et al., Reference Colley, Bustinduy, Secor and King2014).
Upon reaching fresh water, the hatching of eggs takes place; this is facilitated by the lower osmolarity of water, leading to emergence of miracidia. After coming in contact with suitable snail host, Oncomelania spp. in the case of Sj, miracidia develops into mother sporocyst which produces daughter sporocysts. This is followed by emergence of cercaria from the daughter sporocysts about 4 weeks after the snail host has been initially infected (Roberts et al., Reference Roberts, Janovy and Nadler2012; Colley et al., Reference Colley, Bustinduy, Secor and King2014). These cercaria then infect humans by penetrating the skin and shed their tail, becoming schistosomulae. The schistosomulae migrate through venous circulation to lungs, then to the heart, and then develop in the liver. Upon attaining maturation, worms exit the liver through the portal vein system (CDC 2024).
Sj first interacts with the liver when immature worms pass through it, but once the infection by cercaria and maturation of worms is completed in the liver, worms inhabit the mesenteric venules, where they copulate and produce eggs. In the case of Sj, which is mostly confined to Asia, the adult worms are more frequently found in superior mesenteric veins of the small intestine (Rudge et al., Reference Rudge, Carabin, Balolong, Tallo, Shrivastava, Lu, Basáñez, Olveda, McGarvey and Webster2008; McManus et al., Reference McManus, Dunne, Sacko, Utzinger, Vennervald and Zhou2018). However, in some cases, a few eggs travel back to the liver through hepatic vessel instead of ending up in faeces. These eggs then induce granuloma formation (Deslyper et al., Reference Deslyper, Doherty, Carolan and Holland2019).
2. Liver Cancer
LC induction is linked with an array of risk factors. These factors can act alone, but LC induction independently by these factors is extremely unfavourable and LC is generally induced when these factors occur together. Most of them lead to liver fibrosis and cirrhosis, which increases chances of LC induction. Cirrhosis involves replacement of healthy liver tissue with scar tissue which in turns blocks the blood flow to the liver. This interferes with the normal working of the liver, disposing it towards cancer induction (Pinter et al., Reference Pinter, Trauner, Peck-Radosavljevic and Sieghart2016).
Risk factors leading to cirrhosis include infection with hepatitis B and C viruses (HBV and HCV) and chronic alcohol intake. Chronic HBV and HCV infection leads to chronic inflammation of healthy liver tissue which ultimately leads to cirrhosis (Ng & Wu, Reference Ng and Wu2012). Heavy (>80 g ethanol/day) and chronic alcohol intake is also known to be an important risk factor in LC induction which leads to liver cirrhosis in many cases. However, alcohol use can also lead to LC induction without causing cirrhosis (Morgan et al., Reference Morgan, Mandayam and Jamal2004). Similarly, tobacco smoking is another important risk factor in LC induction (Jain et al., Reference Jain, Chaudhary, Varshney, Bin Razzak, Verma, Khan Zahra, Janmeda, Sharifi-Rad, Daştan, Mahmud, Docea and Calina2021).
Non-alcoholic steatohepatitis, commonly known as NASH, is a severe form of non-alcoholic fatty liver disease (NAFLD) and is another important risk factor in LC (Dhamija et al., Reference Dhamija, Paul and Kedia2019). Aflatoxin B1, a chemical produced by fungus and a dangerous food contaminant, is a genotoxic hepatocarcinogen which leads to cancer induction by causing detrimental genetic changes in liver cells (Hamid et al., Reference Hamid, Tesfamariam, Zhang and Zhang2013). Rare genetic and medical conditions including Wilson’s disease (Xu & Hajdu, Reference Xu and Hajdu2008), Porphyria cutanea tarda (Baravelli et al., Reference Baravelli, Sandberg, Aarsand and Tollånes2019), untreated hereditary hemochromatosis (Elmberg et al., Reference Elmberg, Hultcrantz, Ekbom, Brandt, Olsson, Olsson, Lindgren, Lööf, Stål, Wallerstedt, Almer, Sandberg-Gertzén and Askling2003) among other issues are important risk factors in LC induction.
3. SJLC: Are they really connected?
The initial epidemiological studies, mostly carried out in Japan, to find a probable association between Sj infection and LC generated varied results. Several studies conducted in the Yamanashi Prefecture found possible connections between Sj and LC (Inaba, Reference Inaba1987). Three major studies were carried out in this project, specifically from the view point of epidemiology. First, a descriptive study, which found that relative to the country of Japan as a whole, an endemic area of schistosomiasis showed a higher mortality rate for LC (Inaba, Reference Inaba1987). Second, a case-controlled study found higher odds ratio for cases having a history of schistosomiasis but these values were similar to cases which had hepatitis B antigen (Inaba et al., Reference Inaba, Maruchi, Matsuda, Yoshihara and Yamamoto1984). Finally, a retrospective cohort study showed significant higher rates of mortality among male LC patients who were residing in the endemic areas (Inaba, Reference Inaba1984). All these studies pointed towards a strong yet circumstantial link between Sj and LC (Inaba, Reference Inaba1984; Inaba et al., Reference Inaba, Maruchi, Matsuda, Yoshihara and Yamamoto1984; Inaba, Reference Inaba1987).
A similar study in the Yamanashi Prefecture involving subjects who resided in the region between 1973 through 1992 (Takemura et al., Reference Takemura, Kikuchi and Inaba1998) also found possible connections between Sj and LC. It was concluded that chronic effects of Sj could contribute to high mortality rates of LC patients in endemic areas but cautioned about the other etiological factors like alcohol intake and infection with HBV and HCV.
In contradiction to these observations, another study from the Yamanashi Prefecture reported HCC incidences among patients enduring chronic schistosomiasis, but they did not find significant correlation between the same and blamed HCV for the development of HCC in schistosomiasis patients (Iida et al. Reference Iida, Iida, Kamijo, Takaso, Miyazaki, Funabashi, Tsuchiya and Matsumoto1999). A follow-up study in liver cirrhosis patients showed no difference in death rate among patients positive or negative for schistosomal infection, although the sample size in this study was small (from Inaba, Reference Inaba1987).
To avoid the interference by HBV and HCV, a case-controlled study was carried out on hepatitis-negative patients in China. This study concluded that Sj infection probably contributes to both colon cancer and LC (Qiu et al. Reference Qiu, Hubbard, Zhong, Zhang and Spear2005).
A pathological study involving 24 Sj-positive specimens found that Sj on its own, might not be responsible for HCC but probably has a synergistic role in HCC induction along with HBV (Nakashima et al., Reference Nakashima, Okuda, Kojiro, Sakamoto and Kubo1975). An autopsy study on 59 cases also could not generate conclusive evidence to label Sj as a direct factor in HCC induction but also found HBV to play a synergistic role (Kojiro et al., Reference Kojiro, Kakizoe, Yano, Tsumagari, Kenmochi and Nakashima1986).
In specific case studies, fine-needle aspiration and smear preparations have confirmed the co-existence of Sj and HCC (Chen et al., Reference Chen, Chuang, Hsieh, Lin, Hung and Lee2007; Saharti et al., Reference Saharti, Ding, Massarani-Wafai and Pambuccian2018). A study which aimed to analyse the role of a specific heat shock protein in hepatic fibrosis using a mouse model showed Sj infection to be linked with hepatic fibrosis (Huang et al., Reference Huang, Tao, Li, Ma, Xu, Ai, Fan, Jiao and Ning2014). Another study associated enhanced Wnt signalling pathway caused by Sj infection with liver fibrosis (Wang et al., Reference Wang, Chou, Guan, Fang, Lu, Lei, Li and Liu2017). Recently, a similar study which aimed at identifying gut micro-biota signatures in Sj-infected patients highlighted the induction of liver cirrhosis by Sj infection (Gui et al., Reference Gui, Jin, Zhu, Lu, Zhang, Xu, Yang and Xiao2021). Both liver fibrosis and cirrhosis are important events in induction of LC, as discussed later. Yet another study found Sj responsible for significant prevalence of LC tumours in infected patients, among other digestive system tumours (Liu et al., Reference Liu, Ju, Wang, Li and Qiang2023).
4. How is Sj likely inducing LC?
SJLC seem to be induced by an array of factors involving chronic inflammation in response to deposited eggs and secreted egg antigens (SEAs), granuloma formation followed by liver fibrosis and cirrhosis, ultimately inducing changes in genetic makeup and creating significant microenvironment conditions suitable for LC induction. Co-infection with HBV and HCV further facilitates LC induction.
4.1 Chronic inflammation
Liver pathology begins with lodging of schistosomal eggs in the liver sinusoids. These eggs, along with SEAs, trigger a significant T-helper 1 (Th1) type immune response. This involves an increased expression of Th1 type cytokines involving interleukin-1 (IL-1), IL-2, IL-6, interferon gamma, tumour necrosis factor alpha (Stadecker et al., Reference Stadecker, Asahi, Finger, Hernandez, Rutitzky and Sun2004; Butrous et al., Reference Butrous2019; Zheng et al., Reference Zheng, Zhang, Chen, Nie, Miller, Gong and Liu2020; Wang et al., Reference Wang, Tang, Bergquist, Zhou and Qin2023). Though Th-1 type immune response has a killing effect over schistosomes, it appears that humans lack the capacity to eliminate schistosomes, which might also be linked to escape mechanism used by these parasites (Trottein et al., Reference Trottein, Nutten, Angeli, Delerive, Teissier, Capron, Staels and Capron1999). Continuous stimulation by eggs and SEAs lead to an excessive Th1 inflammatory response.
After about four weeks of infection and egg production, the Th1 response shifts towards a Th2 response which exerts anti-inflammatory effects and regulates the immunopathology of Th1 response (Zheng et al., Reference Zheng, Zhang, Chen, Nie, Miller, Gong and Liu2020). This response is marked by heightened secretion of Th2 cytokines involving IL-4, IL-5, and IL-13. These promote polarization of macrophages to M2 type macrophages, creating a microenvironment having a high level of type 2 immune responses which further promotes the formation of granulomas (Oliphant et al., Reference Oliphant, Barlow and McKenzie2011; Yunna et al., Reference Yunna, Mengru, Lei and Weidong2020).
4.2 Granuloma formation
Granuloma formation is supposedly beneficial for the host because it blocks the toxic effects of egg antigens released from the eggs (Morais et al. Reference Morais, Souza, Melo, Aroucha, Miranda, Domingues, Abath and Montenegro2008; Jain & Rana Reference Jain and Rana2024). Once the type 2 immune responses set in, granuloma formation begins. Egg granulomas are generally composed of massive number of lymphocytes, monocytes, macrophages, eosinophils and neutrophils (Liu et al., Reference Liu, Zhang, Liang and Lu2022). Granulomas contain T-lymphocytes of both Th-1 and Th-2 response types (Bogen et al., Reference Bogen, Flores Villanueva, McCusker, Fogelman, Garifallou, el-Attar, Kwan and Stadecker1995).
The core of granuloma might have different immune cells depending upon the species of schistosome that has infected the host (Jain & Rana Reference Jain and Rana2024). Apart from Sj, Schistosoma mansoni (Sm) has also been implicated in LC induction but currently has been assigned to Group 3 of IARC classification (von Bülow et al., Reference von Bülow, Lichtenberger, Grevelding, Falcone, Roeb and Roderfeld2021). Regardless of LC induction, both parasites are capable of granuloma formation. Granulomas elicited by Sj and Sm show distinct cellular composition. Chemokine binding protein secreted by Sm eggs is capable of binding to a specific chemokine and inhibiting its action. It binds to neutrophil chemo-attractant CXCL8 but does not bind to eosinophil chemo-attractant CCL11. This blocks the infiltration of neutrophils but does not block the infiltration of eosinophils as shown in Figure 1, hence leading to a distinct granulomatous pathology where granulomas elicited by Sj will have core mainly of neutrophils, whereas that elicited by Sm will have a core mainly of eosinophils (Figure 1) (Chuah et al. Reference Chuah, Jones, Burke, McManus and Gobert2014; Jain & Rana Reference Jain and Rana2024). While granulomas rarely cause structural liver damage (Culver et al., Reference Culver, Watkins and Westbrook2016), they lead to fibrosis in the periportal space.
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20250208101016363-0517:S0022149X24000762:S0022149X24000762_fig1.png?pub-status=live)
Figure 1. Granuloma’s core composition in case of infection with Schistosoma japonicum and Schistosoma mansoni. Binding of a specific chemo-attractant to chemokine-binding protein secreted by Schistosoma mansoni leads to recruitment of eosinophils in the core of granuloma elicited by it. This is distinct to the core of granuloma elicited by Schistosoma japonicum which is mainly composed of neutrophils.
A study conducted in mice showed that neutrophils can cause major hepatic necrosis and are progenitors of hepatic fibrosis in acute stage of schistosomal infection (Hirata et al., Reference Hirata, Hara, Kage, Fukuma and Sendo2002). The neutrophil core further produces pro-inflammatory cytokines, including IL-1α, IL-1β, IL-6, TNF, CCL3 and CXCL1, which contributes to overall local tissue damage (Chuah et al., Reference Chuah, Jones, Burke, Owen, Anthony, McManus, Ramm and Gobert2013; Llanwarne & Helmby, Reference Llanwarne and Helmby2021). These granulomas ultimately promote severe liver fibrosis, another step in LC induction (Wynn & Cheever, Reference Wynn and Cheever1995).
4.3 Liver Fibrosis
Liver fibrosis involves excessive deposition of extracellular matrix (ECM) in the liver which also involves an up-regulation of ECM production and down-regulation of ECM degradation. These accumulated ECM proteins start distorting the hepatic architecture (Bataller & Brenner, Reference Bataller and Brenne2005). Liver fibrosis occurs in the hepatic sinusoids and portal veins (Hoffmann et al., Reference Hoffmann, Cheever and Wynn2000; Wang et al., Reference Wang, Fan, Lei, He, Wang, Luo, Zhang and Pan2020).
These changes in hepatic architecture are followed by periportal fibrosis, which is also known as periportal hepatic fibrosis (PHF), the most serious manifestation of chronic schistosomal infection. PHF impedes the blood flow and hence impedes the nutrient reach to the liver, causing liver function impairment which can lead to an advanced stage of liver fibrosis leading to cirrhosis. It ultimately leads to portal hypertension and hepatomegaly, splenomegaly and predisposes the infected person to a potential failure of liver if not provided with appropriate treatment (Wiest et al., Reference Wiest, Wu, Zhong, McGarvey, Tan, Yuan, Peters, Olveda and Olds1993; Coutinho et al. Reference Coutinho, McGarvey, Acosta, Manalo, Langdon, Leenstra, Kanzaria, Solomon, Wu, Olveda, Kurtis and Friedman2005; Kamdem et al. Reference Kamdem, Moyou-Somo, Brombacher and Nono2018).
The initiation and progression of liver fibrosis to an advanced stage involves activation and proliferation of hepatic stellate cells (HSCs). Quiescent HSCs (qHSCs) are activated in response to fibrotic stimuli, including chronic inflammatory reactions, to become activated HSCs (aHSCs) (Wynn, Reference Wynn2008; Li et al., Reference Li, He, Guo, Chen and Shan2015). qHSCs are situated in the space of Disse, between hepatocytes and sinusoidal endothelial cells and constitute about 15% of the total liver resident cells. qHSCs play important roles in liver regeneration, vitamin A storage, immuno-regulation among others (Li et al., Reference Li, He, Guo, Chen and Shan2015; Zhang et al., Reference Zhang, Yuan, He, Lei and Wang2016). aHSCs are source of collagen and have the potential to abundantly secrete ECM proteins and tissue inhibitors of metalloproteinases, all of which are responsible for changing the liver architecture (Puche et al., Reference Puche, Saiman and Friedman2013).
A recent study found that schistosomal egg ribonuclease SjCP1412 promotes granuloma formation and accelerates liver fibrosis (Li et al., Reference Li, Li, Yang, Dong, Mei, Lu and Yang2023). Another study which used a mouse model, concluded that aHSCs play an important role in liver fibrosis in Sj-infected host (Huang et al., Reference Huang, Ma, Cao, Zhan, Zhang, Wang, Zhang, Xu and Xia2022a). All these changes lead to an advanced stage of liver fibrosis and cirrhosis, which are major risk factors for HCC (Dhar et al., Reference Dhar, Baglieri, Kisseleva and Brenner2020). Interestingly, an egg antigen Sjp40 supresses HSC activation; however, it appears that it does so to prevent egg death as collagen deposits near the eggs are detrimental for their survival. This observation is supported by the fact that HSCs tend to be located on the margins of granulomas (Zhu et al., Reference Zhu, Yang, Shen, Chen, Chen, Sun, Duan, Zhang, Zhu and Duan2018; Li et al., Reference Liu, Zhang, Liang and Lu2022). Figure 2 shows a proposed mechanism on how Sj infection alone is inducing LC through chronic inflammation and SEAs, leading to fibrosis and cirrhosis and ultimately paving way for carcinogenesis.
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20250208101016363-0517:S0022149X24000762:S0022149X24000762_fig2.png?pub-status=live)
Figure 2. Proposed mechanism of liver cancer induction by Schistosoma japonicum. Deposited eggs lead to inflammation and release SEAs, which causes granuloma formation. Chronic infection and inflammation lead to liver fibrosis and cirrhosis and lead to DNA damage, creating a suitable microenvironment for induction of liver cancer.
4.4 Co-infection with HBV and HCV
Concurrent infections of Sj with HBV or/and HCV can lead to heightened liver deterioration and severe illness and is a risk factor for LC induction (Jain & Rana, Reference Jain and Rana2024). Chronic schistosomiasis coupled with HBV or/and HCV infection not only affects the architecture of hepatocyte arrangement but is detrimental for the viability of hepatocytes (Omar, Reference Omar2019).
A study reported that HBV/Schistosoma spp. concurrent infection from the years 1980–2014 ranged from as low as 9.6% to as high as 64% in Egypt among all reported schistosomiasis patients. For HCV, the figures for same period ranged between 1% in Ethiopia to 50% in Egypt. Same study also collated interesting data on the prevalence of co-infection HCV/HBV and hepatosplenic schistosomiasis (HSS). For HCV, of total patients with schistosomiasis, those with HCV and HSS ranged from as low as 0.06% in China to 40.2% in Egypt, whereas with all the same parameters, the cases for HBV and HSS ranged from 15.8% in Brazil to 58.4% in Egypt (Gasim et al., Reference Gasim, Bella and Adam2015). Concurrent infection of Sj and hepatitis viruses can lead to liver cirrhosis and a synergistic effect can be expected leading to exacerbated liver pathology (Gasim et al., Reference Gasim, Bella and Adam2015).
Studies have reported an increased susceptibility for HBV in patients with chronic schistosomiasis (Zhang et al., Reference Zhang, Xie, Chen, Chen, Dong and Tan2020). While few studies point out that this might be due to frequent blood transfusions which are necessary for chronic schistosomiasis patients (Gasim et al., Reference Gasim, Bella and Adam2015), other studies have rejected the hypothesis altogether for different schistosomal species (Larouzé et al., Reference Larouzé, Dazza, Gaudebout, Habib, Elamy and Cline1987; Ye at al., Reference Ye, Fu, Anderson and Nokes1998). Nonetheless, chronic schistosomiasis and HBV co-infection is expected to end in liver cirrhosis and HCC in advanced cases (Omar, Reference Omar2019).
Moreover, the co-infection prolongs the carriage stage which facilitates chronic hepatitis with significant cirrhosis (Abruzzi et al., Reference Abruzzi, Fried and Alikhan2016). Similar observations were made in patients with chronic schistosomiasis and HCV infection, where a decreased capability of resolving HCV infection was observed in schistosomiasis patients (Kamal et al., Reference Kamal, Rasenack, Bianchi, Al Tawil, El Sayed Khalifa, Peter, Mansour, Ezzat and Koziel2001) and higher liver fibrosis, cirrhosis and HCC were reported (Abruzzi et al., Reference Abruzzi, Fried and Alikhan2016; Omar, Reference Omar2019).
Conversely, an observational study has reported no increase in liver damage in schistosomiasis infected patients who were co-infected with HBV in non-endemic area (Marchese et al., Reference Marchese, Beltrame, Angheben, Marocco, Gaeta and Bisoffi2020).
4.5 Changes at genetic level
As discussed previously, chronic inflammation, granuloma formation, fibrosis, cirrhosis and co-infection with hepatitis viruses are probable factors leading to initiation of SJLC; however, it is important to note that all these factors work simultaneously to induce changes at genetic and molecular level, which ultimately leads to cancer induction.
An important aspect of chronic inflammation is the generation of reactive oxygen species (ROS) (Wang et al., Reference Wang, Li, Ye, Xie and Li2016). During early infection, the activated macrophages contribute to heightened generation of ROS. SEAs induce ROS generation by NADPH oxidase 2 and mitochondria in macrophages, which is essential for M2 macrophage differentiation, which further promotes granuloma formation and fibrosis (Yu et al., Reference Yu, Wang, Wang, Gu, Lei, Tang, Wei, Xu, Wang, Chen, Pu, Qi, Yu, Chen, Zhu, Li, Zhang, Zhou and Su2021). Oxidative stress, exerted by ROS, disrupts normal cell function, interferes with genetic elements and affects signal transduction pathways (Wang et al., Reference Wang, Li, Ye, Xie and Li2016). At genetic level, it induces oxidative damage to both nuclear and mitochondrial DNA, whereas it plays key roles in Wnt/β-catenin and Notch pathways (Li et al., Reference Li, Yu, Yang and Wang2023). All these changes predispose liver towards HCC.
Many studies have linked liver fibrosis and cirrhosis with shortening of telomere length in the hepatocytes (Donati & Valenti, Reference Donati and Valenti2016; Barnard et al., Reference Barnard, Moch and Saab2018; Shin et al., Reference Shin, Park, Yu, Jin, Suh, Lee and Kim2021). This shortening of telomere in hepatocytes has been previously correlated with chromosomal instability which is known to cause hepatoma in humans (Plentz et al., Reference Plentz, Caselitz, Bleck, Gebel, Flemming, Kubicka, Manns and Rudolph2004). Further, telomere length and its shortening has also been linked to HCC diversity (Ningarhari et al., Reference Ningarhari, Caruso, Hirsch, Bayard, Franconi, Védie, Noblet, Blanc, Amaddeo, Ganne, Ziol, Paradis, Guettier, Calderaro, Morcrette, Kim, MacLeod, Nault, Rebouissou and Zucman-Rossi2021). Development of hypoxic environment which is possibly related to cirrhosis has also been reported. The study has labelled this hypoxic liver parenchyma as highly angiogenic (Yu et al., Reference Yu, Chen and Ding2010), another factor probably linked with SJLC induction and progression.
A recent study confirmed the role of B-lymphoma Mo-MLV insertion region 1, a known proto-oncogene, which encodes a crucial histone modifying protein Polycomb group protein in SJLC. The group conducted bioinformatics study where multiple proteins were identified and role of B-lymphoma Mo-MLV insertion region 1 in SJLC was confirmed through molecular studies and studies in mouse models (Sheng et al., Reference Sheng, Chen, Xu, Han, Mao, Chen, Li, Su, Hu, Zhao, Lowe, Huang, Shao and Yao2024).
Further, recent studies have identified siRNA and miRNA, which are derived from Sj, and are capable of inhibiting hepatoma cell growth. In one study, miRNA-7-5p, which was detected in host hepatocytes during Sj infection, inhibited the growth and migration of hepatoma cells. Inhibition was achieved by cross-species down-regulation of the S-phase kinase-associated protein 2 gene in the human hepatoma cell lines in vitro (Hu et al., Reference Hu, Zhu, Wang, Lin, Ma, Zhu, Jiang, Li and Pan2019). In another study, the inhibition was achieved by miRNA-71a, which targeted the FZD4 host gene (Jiang et al., Reference Jiang, Wang, Zhu, Hu, Lin and Pan2022). Detection of these RNAs in human host cells probably hint towards the cancer inducing capabilities of Sj.
One interesting study found up-regulation of glycolysis linked genes during Sj infection. Ldha, Glut4, Pkm2, Pfkfb3, Aldoc and HK2 genes were found to be up-regulated (Xu et al., Reference Xu, Chang, Ni, Li, Chen, Hou and Ji2019). Interestingly, up-regulation of all these genes, except Aldoc, has been directly linked to liver fibrosis and LC as shown in Table 1. While Aldoc gene has not been directly linked with LC, it is known to promote non-small cell lung cancer by regulating Wnt signalling pathway (Shang et al., Reference Shang, Lu, Jiang, Xing, Mao, Yang and Zhang2023). It needs to be determined if Wnt signalling among hepatocytes is also altered by up-regulation of Aldoc gene.
Table 1. Up-regulated glycolysis genes due to Sj infection and their links with liver fibrosis and liver cancer
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20250208101016363-0517:S0022149X24000762:S0022149X24000762_tab1.png?pub-status=live)
4.6 SJLC and LC not linked with Sj
Different mechanisms of cancer induction, both at cellular and genetic level, are observed in SJLC and LC not linked with Sj. As noted previously, LC can be induced by an array of factors not linked with Sj. HBV and/or HCV are independently capable of inducing LC. Hepatitis viruses are capable of insertional mutagenesis of both oncogenes as well as tumour suppressor genes. Hepatocyte transformation is further aided by the accumulation of preS1 large envelope proteins and preS2/S mutant proteins through unfolded protein response (Levrero & Zucman-Rossi, Reference Levrero and Zucman-Rossi2016).
Similarly, multiple factors are responsible for initiating LC in case of tobacco smoking. Tobacco constituents like tar and nicotine not only supress T-cell–related responses but p53 gene reduction is also reported. Chronic smoking further promotes pro-inflammatory cytokines and other toxins which are responsible for necro-inflammation and hepatic lesions and may also cause iron deposition leading to liver fibrogenesis (Jain et al., Reference Jain, Chaudhary, Varshney, Bin Razzak, Verma, Khan Zahra, Janmeda, Sharifi-Rad, Daştan, Mahmud, Docea and Calina2021). Excessive alcohol intake produces similar results, where the pathology begins with a fatty liver proceeding to hepatitis which leads to cirrhosis and ultimately causes HCC (Matsushita & Takaki, Reference Matsushita and Takaki2019).
NAFLD ranges from simple steatosis (fat build-up not linked with alcohol intake) to NASH (excessive amount of fat accumulation in hepatic tissue) (Dhamija et al., Reference Dhamija, Paul and Kedia2019; Peng et al., Reference Peng, Stewart, Woodman, Ritchie and Qin2020). While the exact cause of NASH is unknown, in case of certain obese people with NASH, fat deposition leads to inflammation, fibrosis and further to cirrhosis which transforms into HCC in significant number of patients (Dhamija et al., Reference Dhamija, Paul and Kedia2019; NIH, 2022).
From the previous discussion, although different factors might utilise overlapping mechanisms of inflammation, fibrosis and cirrhosis with a synergistic effect of HBC/HCV infection in HCC induction, the inducing factors are totally different. For example, deposited Sj eggs and SEAs seem to be playing a major carcinogenic through granuloma formation which is seldom reported in other cases discussed previously.
5. SJLC Management
SJLC can be managed at multiple levels, first by stopping the schistosomal infection; second by preventing it from causing severe pathology after infection; third by treating the patients if the infection has led to fibrosis; and fourth by treatment for cancerous stage. The first two levels involve control of schistosomal infections by use of multiple prophylactic techniques (Campbell et al., Reference Campbell, Biritwum, Woods, Velleman, Fleming and Stothard2018) or by treating infection through techniques involving therapeutic vaccines (Molehin, Reference Molehin2020; Molehin et al., Reference Molehin, McManus and You2022) and other new methodologies like use of adjuvants or histone modifying enzymes (Pierce et al., Reference Pierce, Dubois-Abdesselem, Caby, Trolet, Lancelot, Oger, Bertheaume and Roger2011; Pierce et al., Reference Pierce, Dubois-Abdesselem, Lancelot, Andrade and Oliveira2012). These methodologies have been recently covered by us in a related work involving Sj and colorectal cancer (Jain et al., Reference Jain, Rana, Choubey and Kumar2023). The treatment modalities are discussed ahead.
SJLC comes with an extremely complex clinical scenario owing to the result of chronic infection and egg deposition that comes along with granuloma formation, fibrosis and cirrhosis. Along with the Sj infection–linked symptoms, other LC symptoms include abdominal pain, weight loss, malaise and fatigue with an enlarged, irregular and nodular liver that can be detected by physical examination (Szklaruk et al., Reference Szklaruk, Silverman and Charnsangavej2003). The clinical management of SJLC begins with diagnosis, which can involve an array of imaging studies like ultrasound, computed tomography scans and magnetic resonance imaging (MRI). Serum alpha-fetoprotein is sometimes tested as a biomarker for HCC in combination with imaging studies. It can also be used alone, if levels are markedly elevated, which happens in less than 50% cases of HCC at the time of diagnosis (Bialecki & Di Bisceglie, Reference Bialecki and Di Bisceglie2005).
The diagnosis is generally followed by staging and is mostly done by TNM method in most medical organisations. Staging allows to understand the extent of tumour spread inside the liver, vascular invasion and any possible extra-hepatic spread which will further guide the treatment modalities (Szklaruk et al., Reference Szklaruk, Silverman and Charnsangavej2003). For HCC not linked with Sj, the diagnosis and staging measures remain the same however in case of SJLC, MRI is the gold standard for detection of schistosomiasis (Bilgin et al., 2016).
As schistosomal infection leads to fibrosis, liver functions are usually impaired which impacts both the treatment options and prognosis. However, if the pathology has not advanced, liver fibrosis can be managed and events leading to cirrhosis and HCC can be prevented. Interestingly, by this time the normal liver structure is still preserved and lobular architecture is retained with an absence of nodular regenerative hyperplasia, implying that fibrosis could be reversible till some extent (Elbaz & Esmat, Reference Elbaz and Esmat2013). As pathology advances, eggs inside the granulomas lead to formation of marked portal fibrosis which along with angiogenesis leads to schistosomal lesions (Andrade & Santana, Reference Andrade and Santana2010).
Recent studies have highlighted the effectiveness of JQ-1, a bromodomain inhibitor, as a reliable anti-tumour molecule in mouse model. It relieves fibrosis caused by Sj by inhibiting JAK2/STAT3 signalling and can act as a novel therapeutic in controlling liver fibrosis caused by Sj (Ding et al., 2021), thus preventing SJLC induction. Until few years ago, the advanced stages of liver fibrosis, regardless of the reason of fibrosis, could have only been treated by a liver transplant. However, therapies targeting various steps in activation of HSCs, are now being worked upon, which can prevent advanced stages of liver fibrosis and hence preventing cancer induction (Koyama et al., Reference Koyama, Xu, Liu and Brenner2016). Propranolol, a non-selective beta blocker, is used in the clinical management of hepatic schistosomiasis to treat portal hypertension occurring as a result of PHF (Tamarozzi et al., Reference Tamarozzi, Fittipaldo, Orth, Richter, Buonfrate, Riccardi and Gobbi2021).
If the infection has led to a cirrhotic liver and induced HCC, then the choice of surgical or non-surgical methodologies for targeting SJLC depends upon multiple factors including extent of liver involvement, stage of cancer, extent of fibrosis and cirrhosis, vascular invasion and overall patient health. As the arena of non-surgical methodologies for HCC treatment is extremely vast, the same has not been covered here as it would be outside the scope of this work. In short, non-surgical methodologies can be loco-regional or systemic chemotherapy. Loco-regional therapies involve intra-arterial or trans-catheter approaches, local ablative approaches (including chemical ablation and thermal or non-thermal energy-based ablation), radiation-based approaches or a combination of them (Voizard et al., Reference Voizard, Cerny, Assad, Billiard, Olivié, Perreault, Kielar, Do, Yokoo, Sirlin and Tang2019).
However, if regional lymph nodes are involved or if there is an extra-hepatic presence, loco-regional treatment is seldom the choice. Similarly, when main blood vessels of portal system are involved, intra-arterial approaches are not preferred and systemic therapies, including chemotherapy, immunotherapy and targeted therapy, are favoured (Johnson, Reference Johnson2005; Chami et al., Reference Chami, Jarnagin, Abou-Alfa, Harding, Kim, Lin, El Homsi, Crane and Hajj2023). Efficacy of systemic therapies is limited however due to pathologies associated with schistosomal infection relative to cases with no Sj infection.
If the HCC has reached the advanced stages, surgical treatment and liver transplantation are the preferred options. A number of factors govern this decision including tumour size and number, absence of extra-hepatic metastasis, extent of cirrhosis, and overall patient health (Ahmed et al., Reference Ahmed, Safdar, Kemmer, Atiq, Wang and Neff2007; Raza & Sood, Reference Raza and Sood2014). However, in cases where liver transplant is not viable as a result of patient health status and possible metastasis in extra-hepatic regions, palliative care is the only support which can be provided including managing symptoms, reducing pain (Voizard et al., Reference Voizard, Cerny, Assad, Billiard, Olivié, Perreault, Kielar, Do, Yokoo, Sirlin and Tang2019) and decreasing parasitic load.
Discussion
IARC classifies Sj as a possible carcinogen for LC; however, epidemiological and clinical studies suggest a co-relation between LC and Sj infection (Inaba, Reference Inaba1984; Inaba et al., Reference Inaba1984; Inaba, Reference Inaba1987; Takemura et al. Reference Takemura, Kikuchi and Inaba1998; Qiu et al., Reference Qiu, Hubbard, Zhong, Zhang and Spear2005). Further many studies proved that schistosomal infection is playing a central role in hepatic fibrosis and cirrhosis, both of which are important determinants in LC induction (Huang et al., Reference Huang, Tao, Li, Ma, Xu, Ai, Fan, Jiao and Ning2014; Gui et al., Reference Gui, Jin, Zhu, Lu, Zhang, Xu, Yang and Xiao2021; Liu et al., Reference Liu, Ju, Wang, Li and Qiang2023). While these studies offer an idea on an association but they themselves face certain limitations. The studies done by Inaba and Takemura only involves population from Japan, specifically the Yamanashi Prefecture and hence does not paint a global picture. Further, two studies (Inaba et al., Reference Inaba1984; Takemura et al., Reference Takemura, Kikuchi and Inaba1998) also cautioned about other etiological factors for their results, especially HBV and alcohol intake. Another study (Iida et al. Reference Iida, Iida, Kamijo, Takaso, Miyazaki, Funabashi, Tsuchiya and Matsumoto1999) advocated for absence of any such association altogether.
Chronic inflammation and immune responses which are generated as a result of deposited eggs and SEAs seem to be the initial factors in SJLC pathology, which paves the way for granuloma formation followed by liver fibrosis and cirrhosis. All these changes trigger a series of reactions at genetic and cellular level, transforming the normal hepatocytes into cancerous cells. These events are further aided by concurrent infections with HBV and/or HCV. Peculiar genetic changes involve ROS-induced DNA damage which leads to issues such as mutations, sister chromatid exchanges, breakage of DNA strand and disequilibrium of oncogenes and onco-suppressor genes (Herrera et al., Reference Herrera, Benítez-Bribiesca, Mohar and Ostrosky-Wegman2005), all of which contribute to the initiation of LC (Figure 2).
Disruption of metabolic genes specifically linked with glycolysis as a result of Sj infection is one of the most recently developing field which sheds light on the potential of Sj to induce LC by up-regulating these genes (Xu et al., Reference Xu, Chang, Ni, Li, Chen, Hou and Ji2019). As depicted in Table 1, up-regulation of these genes is essential for heightened glycolysis to provide energy for cancer growth and many studies have targeted these genes to slow down HCC.
In contrast to SJLC, other factors which induce LC, might utilise similar pathway for liver carcinogenesis (i.e., liver fibrosis and cirrhosis), leading to genetic changes which is contributing to LC, however, both the inducer (alcohol/ tobacco smoking/ HBV/HCV/NASH) and the genetic changes (e.g., p53 gene reduction due to tobacco smoking), are different. As pointed out previously, p53 gene reduction is observed in the cases of LC induced due to tobacco smoking, while it is possible that p53 gene expression is affected in case of SJLC, however, a specific reduction as in case of tobacco smoking is not reported in literature to date.
Similarly liver inflammation initiates as a result of excess fat deposition in NASH or the liver attains a fatty pathology due to access alcohol, both of which contribute to initiation of LC. However, in case of SJLC, inflammation takes place in response to deposited eggs and SEAs and leads to initiation of LC. While the mechanism of inflammation which is probably inducing LC remains the same however, inflammation itself is triggered by different factors here.
The diagnosis of SJLC is based on imaging studies where MRI is still the gold standard to detect schistosomiasis and LC. Depending upon the diagnosis, a number of techniques can be deployed to manage SJLC ranging from reversing liver fibrosis to certain extent (if infection has not led to LC), to non-surgical and surgical approaches depending upon stage of infection and cancer and overall health of the patient and to a liver transplant if advances stage is reached. However, if there is an extra-hepatic presence or of lymph nodes or blood vessels are also involved, systemic therapies may be the best choice.
With the presented arguments in this work it can be concluded that Sj definitely acts in synergism with other factors, most importantly HBV and HCV, to induce LC. Owing to this synergism its control should decrease cancer cases, at least in endemic regions. It is also likely that Sj can alone induce liver carcinogenesis as observed in a Chinese study (Qiu et al., Reference Qiu, Hubbard, Zhong, Zhang and Spear2005), but these results need to be reproduced at a global scale with a check on other LC inducing factors, so that Sj alone can be labelled as a causative factor for LC. Extensive epidemiological, clinical, pathological and experimental studies are required to precisely examine and understand the probably causative relationship between Sj and LC, or its absence.
Screening of liver tissue from patients who resided in Sj-endemic region and died of LC (and lacked other co-factors), population and case specific studies, are some methods which can provide important data. At genetic level, chemicals generated in response to Sj infection can be tested for their oncogenic potential in a large-scale population which can provide important results. For example, nitrosamines and increased cyclooxygenase-2 in response to infection of urinary bladder with S. haematobium are known to induce oncogenic mutations in oncogenes such as p53, RB, ERBB2 and EGFR (Santos et al., Reference Santos, Santos, Gouveia, Bernardo, Lopes, Rinaldi, Brindley and Costa2021; Jain & Rana, Reference Jain and Rana2024) which leads to urinary bladder cancer. Such analyses among others can help in establishing causality of LC from Sj infection alone beyond any doubt.
Acknowledgements
I would like to acknowledge “smart.servier.com”, an online platform, which was used to make the figures. I would also like to thank Dr. Meenakshi Rana for providing help with Figure 2.
Data availability
Not applicable.
Author contribution
S.J. is solely responsible for all the aspects linked with this manuscript.
Funding source
No funding source.
Competing interest
None declared.
Ethics approval
Not applicable
Consent to participate
Not applicable.
Consent to publish
Not applicable
Clinical trial registration
Not applicable.